Free DNA and Nucleosome Concentrations in Pathological Pregnancies

The study population includes three groups:

Group P: 100 pregnant women with complications typical of placental vascular disease or venous thromboembolism.

Group T1: 30 non-pregnant, healthy volunteers

• The first 15 patients from group T1 will form group T1x. The latter group has two months of additional follow up.

Group T2: 50 pregnant, healthy volunteers

• The first 15 patients from group T2 will form group T2x. The latter group has 7 months of follow-up during pregnancy.

Inclusion Criteria for all patients:

• The patient must have given her informed and signed consent
• The patient must be insured or beneficiary of a health insurance plan

Inclusion Criteria for patients in group P:

• The patient is pregnant and has complications typical of placental vascular disease (preeclampsia, eclampsia, HELLP syndrome, retro-placental hematoma, in utero fetal death) or venous thromboembolism (deep vein thrombosis, pulmonary embolism)

Inclusion Criteria for patients in group T1:

• The patient is available for 3 months of follow-up
• The patient is a non-pregnant healthy volunteer
• No identifiable chronic pathologies
• No history of neoplastic disease
• No history of chronic infectious disease
• No acute disease (such as benign infection), now or within the past two weeks

Inclusion Criteria for patients in group T2:

• The patient is available for 7 months of follow-up
• The patient is pregnant, with no identifiable pregnancy complications
• No identifiable chronic pathologies
• No history of neoplastic disease
• No history of chronic infectious disease
• No acute disease (such as benign infection), now or within the past two weeks

Exclusion Criteria for all patients:

• The patient is participating in another study (with the exception of the following studies: PAPILLO-PMA (2013-A00538-37), ElastoMAP (2013-A01148-37), ElastoDéclenche (2014-A00828-39), LXRs (2009-A00968-49), Bakri (2013-A00914-41), OASIS 2 (2013-A00022-43)).
• The patient is in an exclusion period determined by a previous study
• The patient is under judicial protection, under tutorship or curatorship
• The patient refuses to sign the consent
• It is impossible to correctly inform the patient
• The patient cannot read French
• The patient is receiving hormonal ovarian stimulation in the context of medically assisted procreation
• Impossible to perform venipuncture under good conditions
• New complication or pathology during the study (except for pregnancy complications in group P)

Exclusion Criteria for group P:

• Twin or multiple pregnancy
• The patient is participating in another study (with the exception of those mentioned in the exclusion criteria for all patients and the DG Postpartum study (2013-A00277-38)

Exclusion Criteria for group T1:

• The patient is pregnant
• The patient is breast feeding
• The patient has given birth within the last 3 months
• Known history of chronic disease
• History of treated neoplastic disease
• Acute disease within the past two weeks (includes benign disease)

Exclusion Criteria for group T2:

• Pregnancy with complications
• Known history of chronic disease
• History of treated neoplastic disease
• Acute disease within the past two weeks (includes benign disease)
• Twin or multiple pregnancy